Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date17 Feb 1994 |
Evaluate Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A in Mixed Dyslipidemia Patients
Phase 3 study to evaluate the efficacy and safety of DKP21102_B Added on to DKP21102_A Compared with DKP21102_A
100 Clinical Results associated with Dongkwang Pharm Co. Ltd.
0 Patents (Medical) associated with Dongkwang Pharm Co. Ltd.
100 Deals associated with Dongkwang Pharm Co. Ltd.
100 Translational Medicine associated with Dongkwang Pharm Co. Ltd.